Quantitative assessment of the influence of EPHX1 gene polymorphisms and cancer risk: a meta-analysis with 94,213 subjects

Yang, Xiaoqin; Wang, Yubing; Wang, Guiping

doi:10.1186/s13046-014-0082-9

Journal of Experimental & Clinical Cancer Research

Table 2 Overall and stratified meta-analyses of the association between the EPHX1 His139Arg polymorphism and cancer risk

From: Quantitative assessment of the influence of EPHX1 gene polymorphisms and cancer risk: a meta-analysis with 94,213 subjects

Variables	No^a	Case/control	Homozygote comparison			Heterozygote comparison			Dominant model			Recessive model			Additive model
			OR (95% CI)	P	P^b(I²)	OR (95% CI)	P	P^b(I²)	OR (95% CI)	P	P^b(I²)	OR (95% CI)	P	P^b(I²)	OR (95% CI)	P	P^b(I²)
Total	54	19437/27289	1.05(0.93 ~ 1.18)	0.73	0.09(21.3)	0.96(0.91 ~ 1.01)	0.15	0.02(31.5)	0.97(0.92 ~ 1.03)	0.30	0.00(40.1)	1.02(0.93 ~ 1.13)	0.66	0.23(12.0)	0.99(0.94 ~ 1.04)	0.57	0.00(44.9)
Cancer type
Other	11	3160/4581	0.94(0.75 ~ 1.20)	0.64	0.53(0.0)	0.97(0.87 ~ 1.10)	0.51	0.56(0.0)	0.97(0.87 ~ 1.06)	0.47	0.53(0.0)	0.96(0.76 ~ 1.21)	0.71	0.53(0.0)	0.97(0.89 ~ 1.05)	0.50	0.46(0.0)
Blood	9	2929/3629	0.87(0.67 ~ 1.13)	0.29	0.90(0.0)	0.90(0.81 ~ 1.00)	0.05	0.25(21.4)	0.90(0.81 ~ 0.99)	0.04	0.47(0.0)	0.90(0.70 ~ 1.17)	0.44	0.82(0.0)	0.91(0.83 ~ 0.99)	0.04	0.80(0.0)
Esophageal	3	593/1081	1.30(0.50 ~ 3.38)	0.59	0.07(61.8)	1.02(0.65 ~ 1.62)	0.92	0.03(72.6)	1.06(0.66 ~ 1.73)	0.80	0.01(77.3)	1.30(0.54 ~ 3.13)	0.56	0.10(56.5)	1.10(0.71 ~ 1.69)	0.67	0.01(79.2)
Colorectal	10	5552/7089	1.14(0.85 ~ 1.53)	0.39	0.02(53.5)	0.92(0.85 ~ 0.99)	0.03	0.97(0.0)	0.94(0.87 ~ 1.01)	0.09	0.73(0.0)	1.17(0.87 ~ 1.58)	0.29	0.02(54.0)	0.97(0.91 ~ 1.03)	0.28	0.11(36.8)
Lung	14	4767/8411	1.14(0.83 ~ 1.56)	0.42	0.02(49.3)	1.10(0.94 ~ 1.27)	0.24	0.00(63.4)	1.10(0.93 ~ 1.29)	0.27	0.00(71.9)	0.97(0.80 ~ 1.17)	0.76	0.16(27.2)	1.07(0.93 ~ 1.24)	0.36	0.00(74.1)
Head and neck	4	1035/1075	1.28(0.81 ~ 2.02)	0.30	0.99(0.0)	0.84(0.70 ~ 1.01)	0.06	0.69(0.0)	0.88(0.73 ~ 1.05)	0.14	0.70(0.0)	1.35(0.85 ~ 2.13)	0.20	1.0(0.0)	0.94(0.81 ~ 1.01)	0.41	0.78(0.0)
Breast cancer	3	1401/1423	1.04(0.69 ~ 1.59)	0.85	0.49(0.0)	0.91(0.77 ~ 1.07)	0.04	0.66(0.0)	0.92(0.79 ~ 1.08)	0.30	0.67(0.0)	1.09(0.93 ~ 1.13)	0.70	0.49(0.0)	0.95(0.83 ~ 1.09)	0.44	0.66(0.0)
Source of control
HB	16	5010/5638	1.14(0.93 ~ 1.41)	0.21	0.99(0.0)	0.96(0.88 ~ 1.05)	0.37	0.20(22.7)	0.98(0.90 ~ 1.06)	0.63	0.32(11.4)	1.17(0.95 ~ 1.44)	0.15	0.99(0.0)	1.00(0.94 ~ 1.08)	0.94	0.66(0.0)
PB	36	14191/21351	1.04(0.89 ~ 1.22)	0.61	0.01(39.4)	0.96(0.90 ~ 1.03)	0.22	0.01(39.4)	0.97(0.90 ~ 1.04)	0.40	0.00(50.7)	1.04(0.90 ~ 1.21)	0.56	0.05(30.0)	0.99(0.92 ~ 1.05)	0.64	0.00(57.2)
Ethnicity
Asian	13	2957/3770	0.97(0.75 ~ 1.27)	0.84	0.51(0.0)	0.99(0.89 ~ 1.11)	0.90	0.26(18.6)	0.99(0.89 ~ 1.10)	0.88	0.14(30.6)	0.98(0.76 ~ 1.28)	0.90	0.59(0.0)	1.01(0.90 ~ 1.13)	0.90	0.09(37.1)
Caucasian	32	12294/17831	1.10(0.93 ~ 1.30)	0.26	0.03(34.8)	0.95(0.88 ~ 1.02)	0.18	0.01(44.0)	0.97(0.89 ~ 1.04)	0.39	0.00(52.8)	1.07(0.95 ~ 1.21)	0.27	0.11(24.4)	0.99(0.92 ~ 1.06)	0.71	0.00(57.3)
Mixed	7	3921/5262	0.90(0.73 ~ 1.12)	0.35	0.81(0.0)	0.94(0.86 ~ 1.04)	0.22	0.43(0.0)	0.94(0.86 ~ 1.03)	0.16	0.69(0.0)	0.92(0.74 ~ 1.14)	0.45	0.71(0.0)	0.95(0.88 ~ 1.02)	0.15	0.93(0.0)
African	2	265/426	0.81(0.22 ~ 2.96)	0.75	0.08(21.3)	1.09(0.79 ~ 1.50)	0.60	0.78(0.0)	1.06(0.78 ~ 1.45)	0.69	0.46(0.0)	0.78(0.23 ~ 2.73)	0.70	0.08(66.6)	1.03(0.94 ~ 1.01)	0.84	0.22(34.7)
Smoking status
Smoker	9	2331/2542	1.08(0.64 ~ 1.83)	0.77	0.01(61.5)	1.19(0.88 ~ 1.60)	0.27	0.00(76.6)	1.16(0.85 ~ 1.58)	0.35	0.00(79.9)	1.04(0.68~1.60)	0.86	0.06(46.8)	1.09(0.84 ~ 1.41)	0.52	0.00(80.1)
Non-smoker	8	1498/2336	1.25(0.90 ~ 1.75)	0.19	0.67(0.0)	1.05(0.91 ~ 1.21)	0.49	0.78(0.0)	1.08(0.94 ~ 1.23)	0.30	0.71(0.0)	1.24(0.89 ~ 1.72)	0.21	0.71(0.0)	1.08(0.96 ~ 1.22)	0.19	0.60(0.0)

PB: population based; HB: hospital based. P^b: P-values for heterogeneity from Q test; I² refers to the proportion of total variation owing to between-study heterogeneity.
Bold font marks where fixed effect model used.

Back to article page

ISSN: 1756-9966

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com